Spruce Biosciences Inc. (SPRB) News

Spruce Biosciences Inc. (SPRB): $2.10

0.05 (+2.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SPRB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 390

in industry

Filter SPRB News Items

SPRB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SPRB News Highlights

  • SPRB's 30 day story count now stands at 5.
  • Over the past 10 days, the trend for SPRB's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • The most mentioned tickers in articles about SPRB are RARE.

Latest SPRB News From Around the Web

Below are the latest news stories about Spruce Biosciences Inc that investors may wish to consider to help them evaluate SPRB as an investment opportunity.

Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN FRANCISCO, February 03, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., MPH, Chief Executive Officer, and Samir Gharib, President and Chief Financial Officer, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022 at 5

Yahoo | February 3, 2022

Spruce Biosciences falls 9% amid pipeline update, outlook

Spruce Biosciences (SPRB) provided an update on its clinical programs and financials.The company said it accelerating patient recruitment in the CAHmelia studies, which

Seeking Alpha | January 24, 2022

Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022

SAN FRANCISCO, January 24, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, upcoming milestones and strategic priorities for enhancing the design of and accelerating patient recruitment into the CAHmelia studies, which are evaluating tildacerfont for the treatment of adult classic congen

Yahoo | January 24, 2022

Marquette Asset Management, LLC Buys Vanguard Total Bond Market ETF, ARK Next Generation ...

Investment company Marquette Asset Management, LLC (Current Portfolio) buys Vanguard Total Bond Market ETF, ARK Next Generation Internet ETF, TAT Technologies, Avantis International Equity ETF, Dril-Quip Inc, sells Vanguard Short-Term Corporate Bond ETF, Vanguard Total Stock Market ETF, Vanguard FTSE Developed Markets ETF, Concord Acquisition Corp, Astrotech Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Marquette Asset Management, LLC.

Yahoo | January 20, 2022

Spruce Biosciences (SPRB) Gets a Buy Rating from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Spruce Biosciences (SPRB – Research Report), with a price target of $20.00. The company's shares closed last Wednesday at $3.56, close to its 52-week low of $2.25. According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -22.1% and a 20.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spruce Biosciences with a $9.50 average price target.

Catie Powers on TipRanks | January 6, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | January 6, 2022

Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer

SAN FRANCISCO, January 05, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Dr. Javier Szwarcberg, M.D., MPH, has been appointed Chief Executive Officer and as a member of the board of directors. Samir Gharib, MBA, has been concurrently promoted to President and will continue in his role as Chief Financial Officer.

Yahoo | January 5, 2022

5 Beaten-Down Biotech Bets to Bounce Back in 2022

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

Yahoo | December 31, 2021

Investors Take Advantage Of -7.38% Loss In Spruce Biosciences Inc. (NASDAQ: SPRB)

Spruce Biosciences Inc. (NASDAQ:SPRB) traded at $3.95 at last check on Tuesday, December 21, made a downward move of -7.38% on its previous days price. Looking at the stock we see that its previous close was $4.27 with the days price range being $3.53 $4.36. In terms of its 52-week price range, SPRB has Investors Take Advantage Of -7.38% Loss In Spruce Biosciences Inc. (NASDAQ: SPRB) Read More »

Stocks Register | December 21, 2021

Thinking about buying stock in Prelude Therapeutics, Miniso Group, Galera Therapeutics, Spruce Biosciences, or Purple Innovation?

NEW YORK , Dec. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRLD, MNSO, GRTX, SPRB, and PRPL. Full story available on Benzinga.com

Benzinga | December 21, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5066 seconds.